ArticleJACC. Case reports2026
Off-Label Use of Septal Occluder Devices for Recurrent Tricuspid Regurgitation Following TEER.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent severe tricuspid regurgitation (TR) after transcatheter edge-to-edge repair (TEER) remains a therapeutic dilemma when redo clipping, surgery, or heterotopic caval valve implantation are not feasible. CASE SUMMARY: We report 4 high-risk patients with massive to torrential TR due to interclip coaptation defects who were treated with off-label percutaneous closure using septal occluder devices. Procedural strategy evolved from transfemoral to right internal jugular access to improve coaxial alignment and deployment control. Early atrial septal occluders embolized, whereas muscular ventricular septal defect occluders, with a broader waist, provided stable anchoring and durable TR reduction. Balloon test occlusion and meticulous intraprocedural imaging were essential to avoid iatrogenic tricuspid stenosis. Clinical outcomes ranged from sustained symptomatic improvement to persistent right heart failure in advanced disease. Together, these cases suggest that in anatomically selected patients, occluder implantation may represent a feasible salvage strategy for recurrent TR after TEER when established therapies are not possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.